The FDA had requested clarification and additional information on the data previously submitted by MedImmune in its supplemental biologics license application (sBLA). In this sBLA, MedImmune is seeking
Because PYY is a protein, initial studies focused on PYY delivery by injection. Utilizing its proprietary drug delivery technology, however, Nastech has developed a nasal spray formulation of
Integrase inhibitors are a new class of anti-HIV drugs that block viral replication by preventing the virus from integrating into the genetic material of human immune cells. The
The first product from this long-term partnership is scheduled to launch in the US market during the first half of Meridian’s fiscal 2007. In addition to providing Meridian
Aida has acquired an additional 32.5% of Qiaer Bio-Technology and now owns 77.5% of the total outstanding shares of the company. Qiaer Bio-Technology’s flagship drug is Rh-Apo2L, a
South San Francisco-headquartered Athenagen is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, age-related macular degeneration (AMD) and
The two companies have revealed that, while the analysis of data from their phase Ib study of HCV-796 plus pegylated interferon is still ongoing, data analyzed to date
The study will consist of 90 children between the ages of six months and 18 years of age. In the study, 45 children will receive treatment with EpiCeram
Schering-Plough’s once daily inhaled corticosteroid mometasone, the active ingredient in Asmanex, and Novartis’ once daily beta2-agonist indacaterol (QAB149) will be combined in a single inhalation device. The combined
The guidelines provide clear guidance that physicians should set a treatment goal of reaching undetectable levels of the virus (less than 50 copies/mL) for all HIV patients, including
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.